Our findings of an anti-inflammatory monocyte cluster that is increased in COVID-19 patients, along with suppressive/tissue-repair gene expression changes in monocytes that are accentuated in progressive patients (including CD163, IL1R2, AREG, MRC1, HAVCR2, LGALS9, IL10), support the former evidence. Here, CD163 is linked to COVID-19.